Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

INCA036873

Bispecific antibody · Immune activation, directed at CD70 and CD3 (CD3E) · developed by Incyte

Phase 1 Most advanced trial
INCY Developer
1 Registered trials

What is INCA036873?

INCA036873 is a bispecific antibody and T-cell engager that binds CD70 on tumor cells and CD3 on T-cells. By crosslinking cytotoxic T-lymphocytes with CD70-expressing cells, it redirects and activates them to kill the tumor cells. It is studied in solid tumors and hematologic malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
CD70, CD3 (CD3E)
Mechanism
Immune activation, directed at CD70 and CD3 (CD3E)
Pathways
CD27 costimulatory signaling, CTL-mediated tumor cell killing
Therapy area
Oncology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07195916 Phase 1 Solid Tumors Recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hematologic MalignanciesSolid Tumors

Other drugs acting on CD70 / CD3E

More from Incyte

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind INCA036873

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.